Terminated PHASE2 INTERVENTIONAL NCT00001827

p53 Vaccine for Ovarian Cancer

Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary

Sponsor: National Cancer Institute (NCI)

Interventions aldesleukin in vitro-treated peripheral blood stem cell transplantation incomplete Freund's adjuvant p53 peptide vaccine sargramostim therapeutic autologous dendritic cells

Updated 6 times since 2017 Last updated: Oct 5, 2017 Started: Jul 26, 1999 Primary completion: Dec 17, 2007 Completion: Jan 25, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

This PHASE2 trial investigates Ovarian Neoplasm and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jul 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States